Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO809 CHIM study in healthy participants
NCT05036668Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Novartis. Primary endpoint: Percentage of Participants With Cryptosporidium Infection at Day 10. Started Apr 2022; status: completed.
Beyond the preview
Go deeper on NCT05036668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036668.